NasdaqGS:QUREBiotechs
Why uniQure (QURE) Is Up 15.5% After MHRA Meeting Clears Path For AMT-130 Filing
In April 2026, uniQure reported that a pre-submission meeting with the UK’s MHRA paved the way for a planned third-quarter 2026 Marketing Authorization Application for AMT-130 in Huntington’s disease, based on three-year Phase I/II data showing a statistically significant 75% slowing of disease progression at the high dose with a manageable safety profile.
An interesting aspect of this update is that uniQure aims to leverage long-term, three-year data and ongoing global regulatory...